[go: up one dir, main page]

AR104811A1 - ORAL FORMULATION OF SUSTAINED RELEASE - Google Patents

ORAL FORMULATION OF SUSTAINED RELEASE

Info

Publication number
AR104811A1
AR104811A1 ARP160101559A ARP160101559A AR104811A1 AR 104811 A1 AR104811 A1 AR 104811A1 AR P160101559 A ARP160101559 A AR P160101559A AR P160101559 A ARP160101559 A AR P160101559A AR 104811 A1 AR104811 A1 AR 104811A1
Authority
AR
Argentina
Prior art keywords
sustained release
oral formulation
release formulation
maintaining
cilostazol
Prior art date
Application number
ARP160101559A
Other languages
Spanish (es)
Inventor
Hyun Choi Ji
Jang Jang Jae
Min Cho Sang
Gu Min Byung
Woong Choi Youn
Original Assignee
Korea United Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57441116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Korea United Pharm Inc filed Critical Korea United Pharm Inc
Publication of AR104811A1 publication Critical patent/AR104811A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)

Abstract

Disponiéndose una formulación de liberación sostenida oral, en la que la formulación de liberación sostenida de la presente presenta una velocidad de disolución inicial adecuada y un perfil de disolución capaz de mantener de manera efectiva la concentración de fármaco en el cuerpo, lo que reduce la generación de efectos secundarios mientras que se mantiene la eficacia de cilostazol a pesar de ser tomado una vez al día, y también mejora el cumplimiento terapéutico.An oral sustained release formulation is provided, in which the sustained release formulation herein has an adequate initial dissolution rate and a dissolution profile capable of effectively maintaining the concentration of drug in the body, which reduces the generation of side effects while maintaining the efficacy of cilostazol despite being taken once a day, and also improving therapeutic compliance.

ARP160101559A 2015-05-29 2016-05-27 ORAL FORMULATION OF SUSTAINED RELEASE AR104811A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150076256A KR101748215B1 (en) 2015-05-29 2015-05-29 Oral sustained-release preparation

Publications (1)

Publication Number Publication Date
AR104811A1 true AR104811A1 (en) 2017-08-16

Family

ID=57441116

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160101559A AR104811A1 (en) 2015-05-29 2016-05-27 ORAL FORMULATION OF SUSTAINED RELEASE
ARP240102729A AR134066A2 (en) 2015-05-29 2024-10-08 ORAL SUSTAINED-RELEASE COMPOSITION PREPARED BY MOLDING A COMPOSITION COMPRISING CILOSTAZOL

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP240102729A AR134066A2 (en) 2015-05-29 2024-10-08 ORAL SUSTAINED-RELEASE COMPOSITION PREPARED BY MOLDING A COMPOSITION COMPRISING CILOSTAZOL

Country Status (6)

Country Link
KR (1) KR101748215B1 (en)
AR (2) AR104811A1 (en)
PH (1) PH12015000296B1 (en)
RU (1) RU2696870C2 (en)
TW (1) TWI732762B (en)
WO (1) WO2016195154A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
TWI383809B (en) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd Orally disintegrating powder comprising cilostazol
KR20070024254A (en) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 Sustained-release tablet containing cilostazol
EP2481398A4 (en) * 2009-09-23 2013-03-06 Korea United Pharm Inc EXTENDED RELEASE CILOSTAZOL TABLE WITH IMPROVED DELIVERY RATE AND MINIMIZED SIDE EFFECTS
KR101068475B1 (en) * 2009-12-29 2011-09-28 환인제약 주식회사 Sustained release formulation comprising cilostazol and preparation method thereof
KR20130106456A (en) * 2011-04-29 2013-09-30 한국유나이티드제약 주식회사 Composition for controlled release of drug

Also Published As

Publication number Publication date
TW201707688A (en) 2017-03-01
AR134066A2 (en) 2025-11-26
WO2016195154A1 (en) 2016-12-08
TWI732762B (en) 2021-07-11
KR101748215B1 (en) 2017-06-20
PH12015000296A1 (en) 2017-03-13
RU2017140447A3 (en) 2019-07-17
KR20160141253A (en) 2016-12-08
RU2017140447A (en) 2019-07-02
RU2696870C2 (en) 2019-08-07
PH12015000296B1 (en) 2017-03-13

Similar Documents

Publication Publication Date Title
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX392839B (en) SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT.
MX393610B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX383665B (en) COMPOSITIONS OF DONEPEZIL AND METHODS FOR TREATING ALZHEIMER'S DISEASE.
CO2017008148A2 (en) Nasal powder formulation for the treatment of hypoglycemia
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
CL2015001461A1 (en) A stabilized formulation of pemetrexed.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
UY36761A (en) SOLID ORAL FORMULATION CONTAINING IRINOTECAN AND METHOD 20 OF PREPARING THE SAME
CO2020000240A2 (en) Combination comprising palbociclib and 6- (2,4-dichlorophenyl) -5- [4 - [(3s) -1- (3-fluoropropyl) pyrrolidin-3-yl] oxyphenyl] -8,9-dihydro-7h- benzo [7] annulene-2-carboxylic
CO2017003263A2 (en) Pharmaceutical composition based on anamorelin having activity on cachexia caused by cancer
MX2017008486A (en) Btk inhibitor combinations and dosing regimen.
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
MX394766B (en) IRINOTECAN NANOLIPOSOMIC FOR USE IN THE TREATMENT OF SMALL CELL LUNG CANCER.
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2019002901A (en) Treatment of multiple sclerosis with chs-131.
AR104811A1 (en) ORAL FORMULATION OF SUSTAINED RELEASE
CL2014003326A1 (en) Injectable antioxidant formulation for intravenous use of sodium ascorbate - in high doses, and n-acetylcysteine as oxidizing agents, and deferoxamine as iron chelating agents, plus pharmaceutical excipients; method for administration and use in preventing repertfusion damage in patients with acute myocardial infection, undergoing primary cardiac angioplasty; and kit that contains it.
AR106415A1 (en) PHARMACEUTICAL COMPOSITION FOR PAIN TREATMENT
MX2015007749A (en) Pharmaceutical composition of amanthadine hydrochloride-loratadin e-paracetamol in a capsule for treating colds amongst other allopathy.
EA201692163A1 (en) MEDICINE FOR THE TREATMENT OF PATIENTS WITH TINNITUS
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
PL414926A1 (en) Medical application of N-substituted 3-amino-4-phenyl-5-oxopyrazolino-carboxamide derivatives for the production of a medicine
MX2017014471A (en) CLONIDINE AND / OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY.

Legal Events

Date Code Title Description
FC Refusal